A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent lyme disease

New England Journal of Medicine

Volumn 339, Issue 4, 1998, Pages 216-222

  Sigal, Leonard H ^a,l   Zahradnik, John M ^b   Lavin, Philip ^c   Patella, Sondra J ^a   Bryant, Gary ^d   Haselby, Ray ^e   Hilton, Eileen ^f,g   Kunkel, Mark ^h   Adler Klein, Debra ⁱ   Doherty, Terrence ^j   Evans, Janine ^k   Malawista, Steven E ^k  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Pasteur Merieux Connaught   (United States)

^c Boston Biostatistics   (United States)

^d GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^e MARSHFIELD CLINIC   (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h DANBURY HOSPITAL   (United States)

ⁱ STAMFORD HOSPITAL   (United States)

^j Southeastern Connecticut Med Assoc   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MEB 484 ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; MEMBRANE PROTEIN;

ACTIVE IMMUNIZATION; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BORRELIA BURGDORFERI; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDEMA; FEMALE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION PAIN; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI GROUP; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; LIPOPROTEINS; LYME DISEASE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 0032560790     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199807233390402     Document Type: Article

References (33)

1. Fikrig E, Barthold SW, Sun W, Feng W, Telford SR III, Flavell RA. Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. Immunity 1997;6:531-9.
2. Wormser GP. Prospects for a vaccine to prevent Lyme disease in humans. Clin Infect Dis 1995;21:1267-74.
3. Barthold SW, Bockenstedt LK. Passive immunizing activity of sera from mice infected with Borrelia burgdorferi. Infect Immun 1993;61:4696-702.
4. Barthold SW, DeSouza M, Feng S. Serum-mediated resolution of Lyme arthritis in mice. Lab Invest 1996;74:57-67.
5. Fikrig E, Bockenstedt LK, Barthold SW, et al. Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis. J Infect Dis 1994;169:568-74.
6. Simon MM, Schaible UE, Kramer MD, et al. Recombinant outer surface protein A from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J Infect Dis 1991;164:123-32.
7. Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, Simon MM. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA 1990;87: 3768-72.
8. Fikrig E, Telford SR III, Wallich R, et al. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi. J Exp Med 1995;181:215-21.
9. Telford SI, Fikrig E. Progress towards a vaccine for Lyme disease. Clin Immunother 1995;4:49-60.
10. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990;250:553-6.
11. Fikrig E, Barthold SW, Marcantonio N, Deponte K, Kantor FS, Flavell RA. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun 1992;60:657-61.
12. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun 1992; 60:773-7.
13. Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect Immun 1994;62:1920-6.
14. Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994;271:1764-8.
15. Van Hoecke C, Comberbach M, De Grave D, et al. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 1996;14:1620-6.
16. Schoen R, Meurice F, Brunet CM, et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis 1995;172:1324-9.
17. Erdile LF, Brandt MA, Warakomski DJ, et al. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun 1993;61:81-90.
18. Bacterial endotoxins test. In: The United States pharmacopeia: the national formulary. USP 23, NF 18. Rockville, Md.: United States Pharmacopeial Convention, 1994:1696-7.
19. Sadziene A, Thompson PA, Barbour AG. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis 1993;167:165-72.
20. Lyme disease. MMWR Morb Mortal Wkly Rep 1990;39(RR-13):19-21.
21. Medical dictionary for drug regulatory affairs. Version 1.5. Yokohama, Japan: International Conference on Harmonization (ICH) Medical Terminology (M1) Expert Working Group, November 1996.
22. Schaible UE, Wallich R, Kramer MD, et al. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Vaccine 1993;11:1049-54.
23. Lovrich SD, Callister SM, DuChateau BK, et al. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect Immun 1995;63:2113-9.
24. Gern L, Hu CM, Voet P, Hauser P, Lobet Y. Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine 1997;15:1551-7.
25. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-9):1-12.
26. Kalish R, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 1993;61:2774-9.
27. Idem. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Infect Immun 1995;63:2228-35.
28. Kamradt T, Krause A, Burmester G-R. A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis. Mol Med 1995;1:486-90.
29. Kamradt T, Lengl-Janssen B, Strauss AF, Bansal G, Steere AC. Dominant recognition of a Borrelia burgdorferi outer surface protein A peptide by T helper cells in patients with treatment-resistant Lyme arthritis. Infect Immun 1996;64:1284-9.
30. Lengl-Janssen B, Strauss AF, Steere AC, Kamradt T. The T helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J Exp Med 1994;180:2069-78.
31. Sigal LH. Lyme disease: a review of aspects of its immunology and immunopathogenesis. Annu Rev Immunol 1997;15:63-92.
32. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981;1:377-85.
33. Fahrer H, van der Linden SM, Sauvain MJ, Gern L, Zhioua E, Aeschlimann A. The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk. J Infect Dis 1991;163:305-10.